Assenagon Asset Management S.A. Boosts Holdings in Zoetis Inc. $ZTS

Assenagon Asset Management S.A. raised its position in Zoetis Inc. (NYSE:ZTS) by 134.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,631,619 shares of the company’s stock after buying an additional 935,432 shares during the quarter. Assenagon Asset Management S.A. owned about 0.37% of Zoetis worth $205,290,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after acquiring an additional 419,777 shares in the last quarter. Norges Bank acquired a new position in shares of Zoetis during the second quarter worth about $809,491,000. Nordea Investment Management AB raised its holdings in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Brown Advisory Inc. lifted its position in Zoetis by 5.7% in the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after purchasing an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Zoetis by 14.6% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after purchasing an additional 550,859 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $115.31 on Tuesday. The firm has a 50 day moving average of $124.15 and a 200-day moving average of $130.02. The company has a market cap of $48.68 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.77 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12-month low of $114.36 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the prior year, the firm posted $1.40 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Bank of America boosted their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Finally, Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, March 12th. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.